FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308376054> ?p ?o ?g. }

• W4308376054 abstract "<h3>Background</h3> Transforming growth factor beta (TGFβ) is an immuno-suppressive cytokine commonly present in the tumor microenvironment (TME) that creates considerable challenges for the treatment of solid tumors. Here we describe a unique strategy where induced pluripotent stem cell (iPSC)-derived NK (iNK) and T (iT) cells engineered to express a chimeric TGFβ signal redirector receptor (TGFβ-SRR) block the TGFβ-mediated repressive signaling and redirect the signal to potentiate effector cell function and improve cell fitness. <h3>Methods</h3> To identify iNK cell-specific pathways for TGFβ signal redirection, candidate cytokines were tested for their ability to mitigate suppression of iNK cell anti-tumor activity in the presence of recombinant TGFβ. Next, we developed TGFβ-SRR constructs where selected cytokine endodomains were fused to TGFBR2 ectodomain. TGFβ-SRR constructs were then engineered into iPSCs and differentiated into iNK cells. Phospho-flow for pSMAD2/3 was used to test for blockade of TGFβ signaling in recombinant TGFβ-treated cells. Antibody-dependent cellular cytotoxicity (ADCC) from TGFβ-SRR iNK cells was tested in co-cultures with SKOV-3, PC3, and MDA-MB-231 targets, then measured using xCELLigence readout. Innate killing mechanism was tested via serial restimulation assay with Raji targets and measured by flow cytometry. Co-cultures were performed in the presence of recombinant TGFβ. <h3>Results</h3> Engineered iPSCs expressing candidate TGFβ-SRR constructs were successfully differentiated into iNK cells (>95% CD56+), uniformly expressing TGFβ-SRR transgene (TGFβ-SRR; >95% positive). Analysis for pSMAD2/3 in recombinant TGFβ-treated cells showed 95% reduction of SMAD2/3 phosphorylation in top performing TGFβ-SRR motif, indicating successful blockade of TGFβ signaling. Evaluation of ADCC toward multiple solid tumor lines and using various monoclonal antibodies (Herceptin, Cetuximab, and Avelumab) showed superiority of TGFβ-SRR iNK cells (>80% cytolysis) over parental iNK cell control (<40% cytolysis) in the presence of recombinant TGFβ. Innate killing mechanism was tested in the serial restimulation assay, where TGFβ-SRR iNK cells expanded 3.5-fold over parental iNK cells after the first round of co-culture. Notably, the TGFβ-SRR iNK cells exhibited enhanced functional persistence, completely controlling tumor growth through three rounds of co-culture despite the addition of suppressive quantities of recombinant TGFβ, unlike parental iNK cells which failed to control tumor growth after the first round. <h3>Conclusions</h3> Collectively, the data illustrate that a customized TGFβ-SRR construct can redirect TGFβ-mediated suppression and potentiate effector cell function to enhance the anti-tumor activity of iNK cells. This novel synthetic receptor represents an innovative strategy to enable adoptively-transferred cell therapy to overcome the immunosuppressive TME for the successful treatment of bulky tumors." @default.
• W4308376054 created "2022-11-11" @default.
• W4308376054 creator A5008300500 @default.
• W4308376054 creator A5010828538 @default.
• W4308376054 creator A5016444406 @default.
• W4308376054 creator A5024017005 @default.
• W4308376054 creator A5034862315 @default.
• W4308376054 creator A5050912150 @default.
• W4308376054 creator A5056861387 @default.
• W4308376054 creator A5059754344 @default.
• W4308376054 creator A5067439969 @default.
• W4308376054 creator A5072570750 @default.
• W4308376054 creator A5085664121 @default.
• W4308376054 creator A5085867770 @default.
• W4308376054 creator A5086861101 @default.
• W4308376054 creator A5091390704 @default.
• W4308376054 date "2022-11-01" @default.
• W4308376054 modified "2023-09-25" @default.
• W4308376054 title "259 iPSC-derived NK cells engineered with a novel TGFβ signal redirector receptor exhibit enhanced performance against solid tumors" @default.
• W4308376054 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0259" @default.
• W4308376054 hasPublicationYear "2022" @default.
• W4308376054 type Work @default.
• W4308376054 citedByCount "0" @default.
• W4308376054 crossrefType "proceedings-article" @default.
• W4308376054 hasAuthorship W4308376054A5008300500 @default.
• W4308376054 hasAuthorship W4308376054A5010828538 @default.
• W4308376054 hasAuthorship W4308376054A5016444406 @default.
• W4308376054 hasAuthorship W4308376054A5024017005 @default.
• W4308376054 hasAuthorship W4308376054A5034862315 @default.
• W4308376054 hasAuthorship W4308376054A5050912150 @default.
• W4308376054 hasAuthorship W4308376054A5056861387 @default.
• W4308376054 hasAuthorship W4308376054A5059754344 @default.
• W4308376054 hasAuthorship W4308376054A5067439969 @default.
• W4308376054 hasAuthorship W4308376054A5072570750 @default.
• W4308376054 hasAuthorship W4308376054A5085664121 @default.
• W4308376054 hasAuthorship W4308376054A5085867770 @default.
• W4308376054 hasAuthorship W4308376054A5086861101 @default.
• W4308376054 hasAuthorship W4308376054A5091390704 @default.
• W4308376054 hasBestOaLocation W43083760541 @default.
• W4308376054 hasConcept C1009742 @default.
• W4308376054 hasConcept C104317684 @default.
• W4308376054 hasConcept C107459253 @default.
• W4308376054 hasConcept C118131993 @default.
• W4308376054 hasConcept C145103041 @default.
• W4308376054 hasConcept C170493617 @default.
• W4308376054 hasConcept C203014093 @default.
• W4308376054 hasConcept C2778690821 @default.
• W4308376054 hasConcept C502942594 @default.
• W4308376054 hasConcept C553184892 @default.
• W4308376054 hasConcept C55493867 @default.
• W4308376054 hasConcept C86803240 @default.
• W4308376054 hasConcept C95444343 @default.
• W4308376054 hasConceptScore W4308376054C1009742 @default.
• W4308376054 hasConceptScore W4308376054C104317684 @default.
• W4308376054 hasConceptScore W4308376054C107459253 @default.
• W4308376054 hasConceptScore W4308376054C118131993 @default.
• W4308376054 hasConceptScore W4308376054C145103041 @default.
• W4308376054 hasConceptScore W4308376054C170493617 @default.
• W4308376054 hasConceptScore W4308376054C203014093 @default.
• W4308376054 hasConceptScore W4308376054C2778690821 @default.
• W4308376054 hasConceptScore W4308376054C502942594 @default.
• W4308376054 hasConceptScore W4308376054C553184892 @default.
• W4308376054 hasConceptScore W4308376054C55493867 @default.
• W4308376054 hasConceptScore W4308376054C86803240 @default.
• W4308376054 hasConceptScore W4308376054C95444343 @default.
• W4308376054 hasLocation W43083760541 @default.
• W4308376054 hasOpenAccess W4308376054 @default.
• W4308376054 hasPrimaryLocation W43083760541 @default.
• W4308376054 hasRelatedWork W1582609381 @default.
• W4308376054 hasRelatedWork W1684193236 @default.
• W4308376054 hasRelatedWork W2026841177 @default.
• W4308376054 hasRelatedWork W2055680131 @default.
• W4308376054 hasRelatedWork W2086391872 @default.
• W4308376054 hasRelatedWork W2150149229 @default.
• W4308376054 hasRelatedWork W2162282312 @default.
• W4308376054 hasRelatedWork W4286716220 @default.
• W4308376054 hasRelatedWork W4313427564 @default.
• W4308376054 hasRelatedWork W2946012285 @default.
• W4308376054 isParatext "false" @default.
• W4308376054 isRetracted "false" @default.
• W4308376054 workType "article" @default.